Changes in Bone Turnover With Exposure to a GLP-1 Receptor Agonist
Status:
Terminated
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine changes in bone turnover markers and calcitonin
following the initiation of exenatide compared to placebo in postmenopausal women wtih type 2
diabetes.
Hypothesis 1a: Bone resorption (measured by osteocalcin and bone-specific alkaline
phosphatase) will be lower and bone formation (measured by type I collagen crosslinked
aminoterminal peptide in urine (Urine NTX)) will be higher when subjects are treated with
exenatide compared to when subjects are treated with placebo.
Hypothesis 1b: Calcitonin levels will not vary significantly between periods of treatment
with exenatide vs. placebo.